Leading bank backs European pharma as the cleaner alternative to the AI tradeProactive Investors • 07/08/26
Novo Nordisk: The Stock Price Is Only Beginning To Catch Up With Business FundamentalsSeeking Alpha • 07/04/26
Can Medicare Bridge Help Novo Nordisk Defend Its GLP-1 Leadership?Zacks Investment Research • 07/03/26
Weight Loss ETFs Poised to Rally as Medicare Greenlights GLP-1 CoverageZacks Investment Research • 07/01/26
Medicare will start covering obesity drugs for the first time. Here's what patients should knowCNBC • 06/30/26
Novo Nordisk vs. Viking: Which Obesity Drug Stock Is the Better Buy?Zacks Investment Research • 06/29/26
Seniors in Medicare are about to get landmark obesity drug coverage — but many may not know it yetCNBC • 06/28/26
Why breakthrough GLP-1 weight loss pills may be a bad thing for employer insurance coverageCNBC • 06/26/26
An Analyst Just Declared Eli Lilly the "Clear Winner" of an American Diabetes Association Conference Focused on Weight-Loss Drugs. Novo's Chief Scientist Disagrees.The Motley Fool • 06/25/26
Forget Novo Nordisk. Pfizer's Obesity Pipeline Is Coming, and It Pays You 6.8% While You Wait24/7 Wall Street • 06/23/26
NVO Gains as Foundation Unveils EUR 60M Cardiometabolic Research PushZacks Investment Research • 06/23/26